Biodexa Pharmaceuticals Plc (BDRX) shareholders
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.40+0.02 (+0.84%)
Close on Nov 13, 2026Market cap $5.42MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 225.82B shares
Institutional holders
7
6 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mercer Street Global Opportunity Fund, LLC | 109,396,800 | 9.99% | 13G (passive) | Dec 21, 2023 |
| Bigger Capital Fund, LP | 34,117,200 | – | 13G (passive) amendment | Sep 30, 2024 |
| Sabby Volatility Warrant Master Fund, Ltd. Joint filing with Sabby Management, LLC (9.90%), Hal Mintz (9.90%) | 217,600 | 9.90% | 13G (passive) | Dec 31, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 187,975 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Brio Capital Management LLC Joint filing with Brio Capital Master Fund Ltd. (9.00%) | 167,681 | 9.00% | 13G (passive) amendment | Nov 14, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 26,166 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BDRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 14,809 | 0.00% | $43.09K | New | 0.00% |
| GAMMA Investing LLC | 1,203 | 0.00% | $3.50K | New | 0.00% |
| Allied Private Wealth LLC | 489 | 0.00% | $1.27K | New | 0.00% |
| SBI Securities Co., Ltd. | 29 | 0.00% | $84 | −1 | 0.00% |
| UBS Group AG | 25 | 0.00% | $73 | New | 0.00% |
| Hilton Head Capital Partners, LLC | 6 | 0.00% | $17 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 5 | 0.00% | $15 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 0M | 0.0% | 6 / 0 | 1 / 0 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Fiona Mary Powell | Chief Financial Officer, Director | – | – | Mar 18, 2026 |
| Stephen Anthony Stamp | Chief Executive Officer, Director | – | – | Mar 18, 2026 |
| Stephen Barry Parker | Director | – | – | Mar 20, 2026 |
| Ann Louise Merchant | Director | – | – | Mar 18, 2026 |
| Simon Turton | Director | 2,765 | 0.00% | Mar 18, 2026 |
| Vries Simon de | Director | – | – | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-99.4%
From 1M shares
Short volume, 20 days
33.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biodexa Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 555,208 shares on Sep 14, 2026 over the last 90 days.
See a number that looks wrong?